Connect with us

Russian Sputnik V vaccine production begins in Serbia

AstraZeneca vaccine, Russian Sputnik V vaccine, Serbia, Southern Europe

Health

Russian Sputnik V vaccine production begins in Serbia

Following controversy centering AstraZeneca and Johnson & Johnson vaccines, where several European nations have already halted using AstraZeneca vaccine, demand for Russian Sputnik V vaccine is growing globally. Russian manufacturers of Sputnik V vaccine are receiving large number of requests from various countries in the world with request for supplying this most effective vaccine. Meanwhile, several countries, including Serbia and China are starting production of Sputnik V vaccine due to growing OEM demand.

Moscow announced the start of production of its Sputnik V coronavirus vaccine in Serbia, the first European country outside Russia and Belarus to begin manufacturing the jab.

“Serbia has become the first country in Southern Europe to produce Sputnik V,” the Russian Direct Investment Fund (RDIF), which has backed the financing of the vaccine, said in a statement.

A RDIF spokesman told AFP that Serbia would be the first European country apart from Russia and Belarus to produce Sputnik.

Serbia said that manufacturing would begin on May 20.

Serbian President Aleksandar Vucic is expected to visit Belgrade’s Torlak Institute, where the vaccine will be manufactured, on Thursday.

“The first series of control vials of the Sputnik V vaccine were filled at the Torlak Institute” on Wednesday, Nenad Popovic, Serbia’s innovation minister, said on Twitter.

Serbia began vaccinations with Sputnik in early January.

“The scale of vaccination may be significantly increased thanks to the launch of local production,” RDIF chief executive Kirill Dmitriev said in a statement.

The vaccine could be exported to other countries in the region at a later stage, the fund said.

Russia registered Sputnik V last August ahead of large-scale clinical trials, prompting concern among experts over the fast-track process.

But later reviews have been largely positive, with the medical journal The Lancet publishing results showing it to be safe and more than 90 percent effective.

The vaccine has now been registered for use in dozens of countries.

Please follow Blitz on Google News Channel

Recommended for you:

Contents published under this byline are those created by the news team of WeeklyBlitz

Click to comment

Leave a Comment

More in Health

Advertisement

Popular Posts

Subscribe via Email

Enter your email address to subscribe and receive notifications of new posts by email.

Top Trends

Facebook

More…

Latest

To Top
%d bloggers like this: